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Abstract
School-located vaccination against influenza (SLV-I) has been suggested to help meet the need for 
annual vaccination of large numbers of school-aged children with seasonal influenza vaccine. 
However, little is known about the cost and cost-effectiveness of SLV-I. We conducted a cost-
analysis and a cost-effectiveness analysis based on a randomized controlled trial (RCT) of an 
SLV-I program implemented in Monroe County, New York during the 2009–2010 vaccination 
season. We hypothesized that SLV-I is more cost effective, or less-costly, compared to a 
conventional, office-located influenza vaccination delivery. First and second SLV-I clinics were 
offered in 21 intervention elementary schools (n=9,027 children) with standard of care (no SLV-I) 
in 11 control schools (n=4,534 children). The direct costs, to purchase and administer vaccines, 
were estimated from our RCT. The effectiveness measure, receipt of ≥1 dose of influenza vaccine, 
was 13.2 percentage points higher in SLV-I schools than control schools. The school costs ($9.16/
dose in 2009 dollars) plus project costs ($23.00/dose) plus vendor costs excluding vaccine 
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purchase ($19.89/dose) was higher in direct costs ($52.05/dose) than the previously reported 
mean/median cost [$38.23/$21.44 per dose] for providing influenza vaccination in pediatric 
practices. However SLV-I averted parent costs to visit medical practices ($35.08 per vaccine). 
Combining direct and averted costs through Monte Carlo Simulation, SLV-I costs were $19.26/
dose in net costs, which is below practice-based influenza vaccination costs. The incremental cost-
effectiveness ratio (ICER) was estimated to be $92.50 or $38.59 (also including averted parent 
costs). When additionally accounting for the costs averted by disease prevention (i.e., both 
reduced disease transmission to household members and reduced loss of productivity from caring 
for a sick child), the SLV-I model appears to be cost-saving to society, compared to “no 
vaccination”. Our findings support the expanded implementation of SLV-I, but also the need to 
focus on efficient delivery to reduce direct costs.
Keywords
Cost analysis; Cost effectiveness analysis; School-located vaccination against influenza; 
Randomized controlled trial
1. INTRODUCTION
Seasonal influenza continues to impose a substantial disease burden on children [1–3]. In 
2008, the Advisory Committee on Immunization Practices (ACIP) recommended universal 
childhood annual influenza vaccination, including all children aged 5 to 18 years [4]. ACIP 
also recommends that children aged 6 months-8 years receive two doses of vaccine if they 
have not been vaccinated previously [4]. National influenza vaccination coverage for this 
age group reached 51.0% in the 2010–2011 influenza vaccination season, but has remained 
[5] far below the Healthy People 2020 goal of 80% [6].
Primary care practices may not have the capacity to meet the greatly expanded demand for 
influenza vaccination services [7], which could result in up to 42 million additional 
healthcare visits during a conservative 5-month window for each influenza vaccination 
season[8]. Along with capacity issues, primary care practices also bear financial risks related 
to vaccine purchase and may face inadequate reimbursement rates for administering 
vaccination, which might discourage some practices from expanding their vaccine provision 
[7, 9, 10]. For instance, practices are often fearful of ordering too many vaccine doses that 
they may not use and would have to discard, leading to a financial loss at the end of an 
influenza season [7, 11]. School-located vaccination against influenza (SLV-I) has been 
suggested to help improve vaccination coverage. Cawley and associates conducted a 
systematic literature review and concluded that SLV-I is a promising option to achieve the 
expanded ACIP influenza vaccination recommendation [12]. They also pointed out the need 
for well-controlled trials to establish the cost-effectiveness of specific influenza vaccination 
strategies.
To address this need, we conducted a community-based randomized controlled trial (RCT) 
of SLV-I among elementary school children in Monroe County, NY, during the fall of 2009 
to examine the effectiveness (i.e., improvement in influenza vaccination rates), cost, and 
cost-effectiveness of SLV-I. The study design and the effectiveness of this demonstration 
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have been previously reported [13]. In this paper we report on the cost and cost-
effectiveness of this model of SLV-I. Our first hypothesis is that the average cost per dose in 
SLV-I during the initial year of the study would be comparable or lower than that observed 
in medical practices. Our second hypothesis is that in a cost analysis the average net cost per 
dose in SLV-I would be lower than that observed in medical practices [10], when accounting 
for the costs to deliver vaccines and also parents’ costs to visit medical practices for their 
child’s influenza vaccination. Our supplemental hypothesis was that SLV-I could be cost-
saving for society compared to “no vaccination.” The following Methods section defines 
direct costs, net costs and societal costs to test our first, second and supplemental 
hypotheses, respectively.
2. METHODS
All of the effectiveness parameters and most of the cost parameters were derived from our 
community-based RCT, in developing our cost models and cost effectiveness models.
2.1 Overview of the community-based RCT
Study design and sample size—This study included 21 intervention elementary 
schools (12 urban and 9 suburban; 9,027 students) and 11 control elementary schools (6 
urban and 5 suburban; 4,534 students) in Monroe County (greater Rochester), NY, which 
volunteered to participate in the study [13]. These schools were located in 7 school districts 
[13]. We randomized schools within school districts to either SLV-I or control arms.
Vaccine clinics at school—A vaccination vendor provided influenza vaccination clinics 
at each school, on two dates between 11/3/2009 and 12/18/2009 using a mass vaccination 
team that consisted of at least one registered nurse and a clerical person. The team offered 
both live attenuated (LAIV) and inactivated (TIV) seasonal influenza vaccines, but did not 
offer a separate H1N1 (“pandemic flu”) vaccine in these clinics. All influenza vaccinations 
given in the intervention schools were recorded in the mass vaccinator’s database and 
analyzed in this study.
2.2 Cost analysis
Our cost analysis used the unit of cost per dose. All cost estimates were adjusted to 2009 
dollar values, adjusting with the consumer price index when needed [14]. Five cost 
components were estimated, including three “direct costs” incurred by this study (A) school 
costs, (B) project costs, and (C) vendor costs. Two indirect costs of no SLV-I program, 
averted by having such a program, were also estimated: (D) averted parents’ costs (i.e., costs 
to visit medical practices for a child’s influenza vaccination) and (E) costs averted by 
disease prevention (i.e., both reduced medical costs-- because of reduced disease 
transmission to household members -- and reduced loss of parental productivity related to 
caring for a sick child). “Net cost” is defined as these three direct costs (A+B+C) less the 
indirect Component D (costs to parents). “Societal cost” is defined as the sum of the direct 
costs (A+B+C) less the indirect Component E (costs from disease).
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Direct vaccine administration costs—Component A, school cost, comprises non-labor 
material cost (e.g., supplies and expenses associated with distributing information to 
parents) and labor costs to the schools themselves. Labor cost was calculated by multiplying 
the reported school staff hours by the national mean wage of a relevant job category as of 
May 2009 [15]. Component B, project cost, measured the cost incurred by coordinating 
activities, again including material cost and labor cost. Research and evaluation activities 
were excluded in this estimation. Component C, vendor costs, included the vendor’s labor 
and material costs (e.g., vaccine purchase and supplies). C1 represents the vendor’s relevant 
labor costs. The vendor’s vaccine purchase costs were modeled in two ways. In, our primary 
analysis, we assigned a vaccine purchase cost, C2, of $10.40/dose, which is the weighted 
average prices of TIV (80% of doses administered in this demonstration) and LAIV (20%) 
as of May 2009 listed on the CDC website [16]. We also performed a supplemental analysis 
that estimated the costs assuming that federal Vaccine-For-Children (VFC) doses were free 
(C3) as they are from the viewpoints of school districts, health departments, or insurers. In 
this study, 52% of students were VFC-eligible and therefore there was no charge to the 
vendor or families for the vaccine, but these doses were not “free” from a societal 
perspective.
Indirect (averted) costs—We also estimated two indirect components that are important 
from a broader societal perspective. These components were applied only among the 
children who received an influenza vaccination in the SLV-1 schools. Component D is the 
averted parents’ costs (i.e., to visit medical practices for a child’s influenza immunization). 
From the parent’s perspective, this component is important when comparing the cost of 
immunizing a child in school or at a traditional medical practice setting. The dollar values 
for parents’ time [17–19] ($41.80 for two hours at the national median hourly wage 
regardless of a parent’s employment status) and transportation cost [20] ($6.32) were 
obtained from the literature. The combined value ($48.12) was discounted by 27.1% to 
$35.08, because our analysis of the Medical Expenditure Panel Survey (MEPS) [21] showed 
that 27.1% of children aged 7 to 12 years had at least one primary care visit during an 
influenza vaccination period between 10/1/2007 and 1/31/2008. This group might not need 
an additional medical practice visit solely for influenza vaccination since they would have 
been seen in the practice during the months when influenza vaccine would probably have 
been available there. We used this as a conservative estimate; some of these parents would 
have scheduled an additional primary care visit for influenza vaccination and, in some cases, 
children would not have been immunized during visits associated with acute illnesses [22].
As a supplemental analysis, we estimated Component E, the costs averted by disease 
prevention (i.e., both reduced medical costs-- because of reduced disease transmission to 
household members -- and reduced loss of parental productivity from caring for a sick 
child), using the assumptions derived from the literature as follows. Based on data from a 
large controlled clinical trial, Schmier et al. estimated the averted medical expenditure to be 
$117.45 (adjusted to 2009 dollars) for all members in a household during an influenza 
season [23]. This averted medical expenditure represents the difference in direct influenza 
costs between intervention and control schools. These costs include outpatient, emergency 
department, hospitalization, prescribed medication and over-the-counter medication [23]. 
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Schmier et al. also calculated the averted productivity loss as $87.55 (adjusted to 2009 
dollar) per household, in addition to the averted medical expenditure of $117.45 [23]. They 
based this calculation on assumptions regarding the forgone income of a parent who was 
absent from work to take care of her/his influenza-infected child. Their study reported that 
the difference in the vaccination rate between the intervention group and the control group 
was 45 percent (47% in intervention group versus 2%in controls), and that the average 
household size was 4.6 members (2.6 children and 2.0 adults) [23]. Thus, Component E 
could be inflated by 2.22 (=1/45%) times, if the difference in the vaccination rate is 100%, 
i.e., $455 (=2.22*($117.45+$87.55) per household.
Monte Carlo Simulation—To address the uncertainty of the cost estimates in our study, 
we conducted a Monte Carlo simulation in summing the component costs, (A), (B) and (C1), 
to estimate subtotal costs and total costs. For each component cost we defined a triangular 
distribution with likeliest, minimum and maximum values based on prior studies that 
documented factors affecting vaccination costs [10]. The likeliest value was the overall 
mean of the SLV-I schools. The minimum and the maximum values were selected among 
the four subgroups of the SLV-I schools, based on geographic area (urban or suburban) and 
the intensity of communication to parents (some schools were randomized to a high intensity 
of communication with many parent reminders; others to low intensity)[13]. We reported the 
mean and the 95% confidence interval (CI) of the simulation results with 10,000 iterations.
Comparison with practice-located vaccination—This cost analysis was designed to 
examine our first and second hypotheses, i.e., that the cost of SLV-I is comparable or less 
than the cost of practice-located childhood influenza vaccination, depending on the 
assumptions in the cost calculation. We determined that SLV-I would be less costly if the 
estimated cost per dose for SLV-I were below the mean/median ($38.23/$21.44 in 2009 
dollar value) cost per dose for practice-located influenza vaccination as reported in our past 
study [10]. For this analysis, we consistently excluded the vaccine purchase cost from both 
SLV-I costs and medical practices’ costs [10]. Thus, vaccine costs did not affect this 
comparison. The mean value ($38.23) was not published in our past study, but calculated 
with the same subjects as in our past study [10]. To test this second hypothesis, the averted 
parent’s cost to visit a medical practice for their child’s vaccination had been subtracted 
from the SLV-I costs.
Supplemental cost analyses of first and second SLV-I clinics—Children aged 6 
months-8 years are recommended to receive two doses of vaccine if they have not been 
vaccinated previously [4]. Children could receive a vaccine dose at their primary care 
physicians’ office before the first school-located clinic (“first clinic”) and/or before the 
second school-located clinic (“second clinic”). Of the 1724 doses provided in SLV-I 
schools, the first clinics provided 70% of doses (1200, i.e., 1197 first-doses +3 second-
doses) and the second clinics provided 30% (524, i.e., 184 first-doses + 340 second-doses). 
If we assumed that the total administrative costs to the vender were equally distributed 
between the first and second clinics for each school, the per-dose cost estimates would be 
much lower in first clinics since more doses were administered in these. Therefore, we 
conducted separate supplemental analyses for first clinics and second vaccine clinics. We 
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conducted additional supplemental break-even analyses to assess the threshold values at 
which SLV-I would be equivalent to medical practice-located vaccination in direct costs or 
net costs.
2.3 Effectiveness and cost parameters in the cost effectiveness analysis (CEA) model
Effectiveness measure parameters—The effectiveness measure was the receipt of at 
least a first dose of seasonal influenza vaccination, a metric also used by prior studies [13, 
24]. This measure was adopted because our database could not distinguish which children 
needed two doses due to the lack of a prior seasonal influenza vaccination. The primary 
effectiveness measure was the difference in the percent of children vaccinated (either at 
school or elsewhere) at the intervention vs. control schools; i.e., the incremental vaccination 
rate (regardless of the setting in which influenza vaccine was given). This difference could 
lead to either a positive or negative change in terms of vaccination receipt. The secondary 
effectiveness measure was the incremental vaccination rate solely based on vaccination 
administered in SLV-I schools.
Cost parameters—The cost parameters of CEA followed the cost analysis illustrated 
earlier, i.e., the primary cost measure included the direct cost from a narrower societal 
perspective. The secondary cost measures included the indirect costs.
Cost-effectiveness measures—The incremental cost-effectiveness ratio (ICER) was 
estimated by dividing the incremental cost by the incremental effectiveness (i.e., the number 
of additionally vaccinated students), using either control schools or “no-vaccination” as a 
reference group. Two types of ICERs were estimated separately for the primary and 
secondary effectiveness measures, explained above.
3. RESULTS
3.1 Effectiveness measures
In SLV-I schools, 15.3% of the children received their first dose of seasonal influenza 
vaccination at school (our secondary effectiveness measure) (Table 1). In addition, 27.4% of 
the children attending SLV-I schools were vaccinated elsewhere. The overall vaccination 
rate, irrespective of the location of vaccination, was 42.7% in SLV-I schools (Table 1) 
compared to 29.5% in control schools (p-value < 0.0001). Thus, the net effect of SLV-I was 
a 13.2 percentage point higher influenza vaccination rate, i.e., our primary effectiveness 
measure. This primary effectiveness measure (13.2%) was lower than the secondary 
effectiveness measure (15.3% vaccinated at schools) due to the fact that the proportion of 
children vaccinated with influenza vaccine elsewhere was smaller among children attending 
SLV-I schools than control schools.
Among the 1,381 students who received their first vaccine dose in an SLV-I school, 1197 
(87%) did so at their school’s first vaccine clinic rather than at the school’s second clinic. 
Therefore, we also calculated the effectiveness of these first clinics only, i.e., excluding 
second clinics. These first clinics alone increased the proportion of children receiving 
influenza vaccine overall (the primary effectiveness measure) by 11.2 percentage points 
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when compared to the control schools (Table 1). Overall, 13.3% of children attending SLV-I 
schools were vaccinated during the first clinics (secondary measure) (Table 1).
3.2 Cost analysis
Per dose costs by component—The mass vaccinator documented administration of 
1724 vaccine doses among 1381 students initiating their first dose of the influenza series. 
This was used as the denominator for this cost analysis (Table 2). The school cost 
(Component A) was $9.16 per dose, and was composed of per-dose material costs ($4.42) 
and labor costs ($4.75). Per dose project costs (B) were $23.00 and vendor costs (C, 
including vaccine purchase and administration) were $32.67. The direct costs (school + 
project + vendor costs) totaled $67.13 with 95% CI ($56.91, $78.06) in our Monte Carlo 
simulation.
The indirect cost components –Component D, averted parents’ costs, and E, costs averted by 
disease prevention), were estimated to be $35.08 and $455.00 (not reported in Tables) per 
dose, respectively.
Per dose cost comparisons—When we accounted only for direct costs without vaccine 
purchase, the overall cost per dose was estimated to be $54.26 with 95% CI ($44.10, $65.16) 
(Subtotal Cost 2, Table 2). This per dose direct cost ($54.26) is above the mean/median 
($38.23/$21.44) and the 75th percentile ($38.84) direct cost for providing influenza 
vaccination in medical practices as reported in our previous study [10]. This estimate was 
against our first hypothesis that the average direct cost per dose in SLV-I during year 1 
would be comparable or lower than that observed in medical practices.
Because the vaccine purchase cost (C2) could vary substantially across schools depending 
on the proportion of VFC eligible children, we made separate costs estimates: (i) including 
the vaccine administration cost (C1) only and (ii) additionally including the vaccine 
purchase cost (C2).
When we accounted for the Component D, averted parental cost to accompany their child to 
a medical practice for immunization (which was averted by SLV-I), this cost declined to 
$19.26 (Total Cost 2, Table 2). This per dose net cost ($19.26) falls between the 25th 
percentile ($13.42) and the mean ($38.23) cost for providing influenza vaccination in 
medical practices reported in our previous study [10]. Therefore, this cost analysis supported 
our second hypothesis that SLV-I has lower net costs compared to conventional influenza 
vaccination in medical practices.
Per dose costs for first and second clinics—The SLV-I vaccine net costs, 
accounting for averted parental cost to accompany a child to a medical practice for influenza 
vaccination, were $19.26 when considering all vaccine clinics (both first and second). They 
were $3.90 if only first clinics were included (Table 3), well below both the 25th percentile 
($13.42) and the mean ($38.23) cost per dose in private medical practices [10]. If only first 
clinics were included (Table 3), per dose direct cost ($39.06) (without considering the 
averted parent’s cost to visit medical practices) is comparable to the mean ($38.23) cost for 
providing influenza vaccination in medical practices as reported in our previous study [10].
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3.3 Cost effectiveness analysis
Tables 2 and 3 present the CEA results for all influenza vaccination clinics and for first 
clinics alone, respectively. The CEA that included only first clinics was far more favorable 
for SLV-I than vaccination in medical offices. Specifically, if only first clinics were 
included, the estimated ICER (based only on Components A + B + C1) decreased from 
$73.70 (Table 2) to $53.10 (Table 3) per-incremental-student-vaccinated.
This ICER increased depending on the additional assumptions of the vaccine purchase cost. 
For all influenza vaccination clinics, the ICER increased from $73.70 to $84.47 (assuming a 
cost of $0 for influenza vaccine provided by the VFC program from the perspectives of 
school districts and the local health department) to $92.50 (assuming $10.40 as the cost of a 
dose of influenza vaccine provided by the VFC program from a societal perspective), 
respectively (Table 2). The perspectives of school districts and the local health department 
were adopted, because these perspectives are the factors that school districts and the local 
health department would use in considering a future school-vaccination program (i.e., they 
would not consider the cost of VFC vaccine, which is government supplied).
More broadly, the ICER would decline if indirect costs averted by parents (D) are taken into 
account (Components A+B+C – D). If we consider the savings for parents who would 
otherwise need to visit medical practices for their children’s influenza vaccination 
(Component D), the ICER of $92.50 in direct costs (including both labor and vaccine 
purchase) declined to $57.37 in net costs (Table 2).
Our supplemental hypothesis was that SLV-I could be cost-saving for society compared 
to ”no vaccination.” This hypothesis is supported by our findings. That is, if indirect costs 
averted by disease prevention (E) are taken into account (Components A+B+C – E), the 
ICER became negative in societal costs ((A+B+C-E) = $67.13-$455=-$387.87) (results not 
shown in Tables 2). The negative ICER values indicate that SLV-I is cost-saving compared 
to ”no vaccination” from the broader societal perspective.
Additionally, we performed a supplemental break-even analysis for CEA accounting for net 
costs [i.e., (direct costs – parent costs) = (A+B+C – D)]. This analysis suggests SLV-I could 
be cost-saving to society in net costs -- even if averted costs due to medical expenditures and 
lost productivity are not included -- if the vaccination rate at school were to increase from 
the actual level in this project (15.3%) to at least 29.5%.
4. DISCUSSION
4.1 Implications based on key findings
This study provides both caution and also support for the benefit of SLV-I. In the first year 
of the SLV program, direct per-dose costs were higher for SLV-I ($54.26/dose) than those 
for pediatric practice-based influenza vaccination (previously reported mean/median cost 
$38.23/$21.44 per dose). However, when we factored in the averted costs for parents to have 
their child vaccinated by the child’s primary care provider, which is averted by SLV-I, our 
cost analysis showed that the (average) net cost estimates per dose in the SLV-I schools 
were lower than those in pediatric practices, particularly for the first vaccination clinics in 
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the SLV-I program. Finally, because SLV-I was associated with an increase in influenza 
vaccination, savings from the increase in disease prevention could be included in the model. 
This analysis showed SLV-I to be cost-saving to society compared to “no vaccination.”
Direct costs (costs to deliver influenza vaccinations)—In this SLV-I 
demonstration project direct costs (A+B+C1=$54.26) were higher than practice-based costs 
($38.23). If SLV-I could reduce the direct cost of providing influenza vaccination in school, 
the program could reach the break- even point (versus medical practices), irrespective of 
indirect costs. Our analyses identified three feasible strategies to make SLV-I less costly and 
more cost effective than vaccination in medical practices, even without accounting for any 
future indirect cost savings. The first strategy is elimination of the relatively poorly attended 
second dose clinics. Children eligible for a second dose could be referred to primary care. 
Another strategy is to maximize vaccination clinic size through better student recruitment. 
We believe that as schools and parents become more familiar with SLV-I, the program will 
attract a larger number of children and eventually achieve the break-even threshold. 
Specifically, if this SLV-I project could have achieved a higher vaccination rate, providing 
2447 doses (42% more than the actual 1724 doses given), this SLV-I demonstration would 
reach the break-even point. The third strategy involves decreasing direct costs through 
greater efficiency. For example, streamlined utilization of SLV-I personnel may be realized 
with more experience. Substantial project administration time was spent on the consent 
process that could be streamlined in the future through the use of technology such as 
electronic consent. A combination of these three strategies is the most promising 
enhancement to SLV-I.
Net costs including averted parent costs—When averted parental costs are 
considered, the estimated per dose net cost ($19.26) is below the mean/median cost 
($38.23/$21.44) for providing influenza vaccination in medical practices [10]. This estimate 
decreases to $3.90 if only first clinics were included, which is well below both the 25th 
percentile ($13.42) cost per dose in private medical practices [10]. These cost estimates 
supported our second hypothesis that SLV-I has lower net costs compared to conventional 
influenza vaccination in private medical practices, if averted parent costs are included in the 
calculation.
Costs to society—Moreover, our cost analysis showed that SLV-I was cost-saving to 
society compared to no-vaccination. This analysis accounted for direct costs and costs 
averted by disease prevention (i.e., both reduced medical costs-- because of reduced disease 
transmission to household members -- and reduced loss of productivity from caring for a 
sick child) at the household level (Component E), as reported earlier. It is important to note 
that the magnitude of Component E can vary across influenza seasons due to year-to-year 
variation in both the virulence of the particular season’s influenza virus and vaccine 
effectiveness. Due to such uncertainty, Table 2–4 did not include the results relating to this 
component.
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4.2. Comparisons to other studies
In our SLV-I model, a for-profit vendor delivered the in-school vaccinations that were 
purchased through routine channels. Thus, estimates of the costs for this study tend to be 
larger than those in other SLV-I demonstrations. Our estimate of $54.26 per dose was 
substantially higher than $6.75 estimated by Schmier et al. [23], the $9.78 estimated by Hull 
and colleagues [25] and the $15.14 estimated by Effler and associates [24]. Among these 
studies, only the last study reported the detailed cost items within the administration cost. 
Regarding the labor cost estimates, our estimate ($37.27 per dose) was higher than $11.79 of 
Effler et al [24]. The study by Hull and colleagues [25] may have underestimated the true 
administrative cost, because their demonstration did not seek third party reimbursement 
(which was included as part of the vendor’s administrative cost in our study). One of the 
reasons for this difference could be our extended time and effort that was needed to collect 
parents’ consent forms; these forms contained detailed information about patient insurance. 
Material costs incurred by schools and the project coordinators were $5.40 per dose, which 
was comparable to $5.53 (adjusted to 2009 dollar) estimated by Effler et al [24]. However, 
our estimate of the vendor’s material cost, $16.02 per dose, was much larger than that of 
$1.59 by Effler et al [24]. This gap can be partly explained by our additional inclusion of 
items such as the refrigerator for vaccines and non-medical supplies.
Other studies also have found SLV-I to be cost saving to society, when accounting for 
broader indirect costs [23, 26]. White and colleagues conducted a similar CEA among 
school-aged children using secondary datasets only [26]. They concluded that group-based 
influenza vaccination is cost-saving, i.e., saving $6.19 and $53.98 per vaccination as 
compared to individual-initiated vaccination (at a conventional medical practice) and no-
vaccination, respectively. Their estimate about SLV-I cost (including all administrative and 
vaccine purchase costs) was $6.69 adjusted to 2009 dollars. This amount seems extremely 
low considering the vaccine purchase cost of $10.40 per dose listed by CDC [16].
Schmier et al. conducted a cost analysis of SLV-I using primary data from a large-cluster 
controlled clinical trial [23]. They compared the cost per household between intervention 
schools and control schools, and concluded that SLV-I targeting children aged 5–18 years is 
cost- saving to society. In their estimates, the households in intervention schools incurred an 
additional incremental cost to have a child receive an influenza vaccination ($40.31), which 
was offset by the averted medical expenditure ($117.45) and lost productivity ($87.55) per 
household.
4.3 Potential limitations
One potential limitation is the assumption of equal direct costs for first vaccine clinics and 
second clinics in the SLV-I schools. Since it was difficult to strictly allocate costs for each 
clinic, we assumed an equal allocation. The true cost for first clinics is likely to be between 
the estimates in Table 2 (first and second clinics) and Table 3 (first clinic only). Also, as 
mentioned earlier, the administrative cost is expected to decline over multiple seasons. 
Hence, our estimates in Table 2 are likely to be conservative ones.
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Due to the lack of information on whether children were due for one or two doses of 
influenza vaccine based on the available data, our study’s outcome variable was the receipt 
of at least one dose rather than being fully immunized.
A third limitation involves generalizability of our estimates, which may have been limited 
by three factors. First, our SLV-I program occurred during the 2009–2010 vaccination 
season during which there was the H1N1 influenza pandemic. This outbreak may have 
affected the vaccination behaviors of our study population in unmeasured ways. For 
instance, demand for seasonal influenza vaccine may have been affected by the lack of 
availability of H1N1 vaccine as part of the SLV-I program. Second, the effectiveness of 
SLV-I depends on the proportion of local children vaccinated by medical practices before 
the school vaccine clinics. That is, when medical practices regularly vaccinate a high 
proportion of children in a certain area, the SLV-I program in that area is likely to only have 
a small impact due to a “ceiling-effect.” Therefore, our estimates of SLV-I effectiveness are 
likely to be most applicable to other settings where the “baseline” vaccination rates 
contributed by medical practices are comparable to those in our study site (29.5%). Third, 
seasonal influenza’s severity varies across regions during the same season. Because seasonal 
influenza’s severity may affect influenza vaccination behavior [27], SLV-I effectiveness 
might be different in other regions even if the baseline vaccination rates in those regions are 
comparable to that of our study. Additionally, we did not include costs associated with 
disruptions of the school day caused by SLV-I, nor cost savings associated with decreased 
absenteeism.
Another limitation is that the indirect cost estimates were not derived from our study, but 
from the literature. However, the indirect cost component (D, averted parents’ costs) used a 
national-level median hourly wage among working adults and, hence, is likely to be 
reasonably applicable for our study population. Because another indirect component (E, 
costs averted by disease prevention) has uncertainty in the methods and the magnitude 
across the seasons, we did not report component E-related results in Tables.
4.4 Conclusion
Our empirical results appear to support the expanded implementation of SLV-I. Future work 
is needed to examine the feasibility of improving delivery efficiency by offering one clinic 
instead of two clinics for each school, and increasing the vaccination rate within SLV-I. 
Direct medical costs to conduct SLV-I (school + project + vendor costs) were high in this 
initial year of the SLV-I intervention, exceeding typical reimbursement rates. However, 
costs potentially could be decreased over time as greater efficiencies may accrue in 
subsequent years of the intervention. Nevertheless, costs currently favor SLV-I over the 
conventional influenza vaccination delivery system either when we only consider a single 
SLV-I clinic per school or if averted parental costs to visit medical practices are taken into 
account. One major challenge is that cost-savings to parents may not be a factor that is 
considered by schools or the medical care system when SLV-I is contemplated. Nonetheless, 
our findings lend support to SLV-I as a potentially promising system to raise childhood 
influenza vaccination rates in a cost-efficient manner.
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We estimate a school-located flu vaccination project’s cost and cost-effectiveness.
A randomized controlled trial of urban and suburban vaccination provides our data.
The direct per-dose cost of this project exceeded that of office-based vaccination.
When we include broader averted costs, the program was less costly than office-
based vaccination.
Our findings support expanded program implementation and suggest efficiencies.
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Table 2
Cost analysis and cost-effectiveness analysis of school-located seasonal influenza vaccination (SLV-I) during 
the 2009–2010 season (2009 dollar value)
Cost analysis a Cost-effectiveness analysis b
Vaccinated at school Vaccinated anywhere c
Cost ($ per dose) ICER d ($-per-incremental-student- vaccinated)
COMPONENT COSTS e
(A) School Cost f $9.16 ($5.92, $13.61) $11.45 ($7.39, $17.01) $13.29 ($8.90, $16.84)
(B) Project Cost g $23.00 ($14.85, $34.17) $28.73 ($18.55, $42.68) $33.37 ($22.35, $42.29)
(C) Vendor Cost (= C1+ C2 ) $32.67 ($25.63, $42.34) $40.81 ($32.01, $52.87) $47.40 ($37.87, $55.11)
 (C1) vaccine administration h $19.88 ($12.84, $29.55) $24.84 ($16.04, $36.90) $28.85 ($19.32, $36.56)
 (C2) vaccine purchase (VFC dose =$10.40i $12.79 $15.97 $18.55
 (C3) vaccine purchase (VFC dose = $0)i $7.31 $9.13 $10.61
(D) Averted parents’ costs (i.e., to visit medical 
practices for a child’s influenza vaccination)
$35.08 $35.08 $35.08
SUBTOTAL COSTS j
Subtotal Net Cost 1: (A + B) - (D) −$1.53 (−$9.47, $6.92) $6.90** (−$2.92, $17.54) $10.62*** ($2.05, $18.88)
Subtotal Direct Cost 2: (A + B + C1) $54.26 ($44.10, $65.16) $67.86 ($55.06, $81.71) $73.70 ($62.67, $84.60)
Subtotal Direct Cost 3: (A + B + C1 + C3) $61.66 ($51.36, $72.58) $76.97 ($63.91, $90.58) $84.47 ($73.48, $95.06)
TOTAL COSTS j
Total Direct Cost 1: (A + B + C) $67.13 ($56.91, $78.06) $83.67 ($70.83, $97.40) $92.50 ($81.47, $103.24)
Total Net Cost 2: (A + B + C1) - (D) $19.26* ($8.70, $30.10) $32.74 ($20.00, $46.48) $38.59 ($27.57, $49.30)
Total Net Cost 3: (A + B + C) - (D) $31.97 ($21.78, $42.97) $48.70 ($35.65, $62.58) $57.37 ($46.26, $68.11)
a
Based on 1724 doses.
b
Based on 1381 students, identified as receiving at least the 1st dose at the SLV-I schools in the vendor’s data.
c
Broader perspective accounting for the fact that among children attending SLV-I schools a smaller proportion of children were vaccinated 
elsewhere (i.e., their primary care doctor’s office) than control schools. Namely, Incremental effectiveness declined from 15.3% to 13.2% ICER for 
components (A/B/C1) inflated by (15.3%/13.2%).
d
ICER = incremental cost-effectiveness ratio [$-per-incremental-student-vaccinated at least 1st dose in the school-located seasonal influenza 
vaccination (SLV-I), compared to control schools]
e
The values in the rows for COMPONENT COSTS indicate the triangular distributions defined by the likeliest value, (minimum value and 
maximum value). The likeliest value is the overall mean of the SLV-I schools. The minimum and the maximum values were selected among the 
four subgroups of the SLV-I schools, based on geographic area (urban or suburban) and the intervention intensity (high or low).
f
Composed of material cost and labor cost. Material cost includes information distribution (to parents) costs such as paper, mailing, and phone. 
Labor cost was calculated through “the time spent for the project by school staffs” multiplied by “category-specific hourly wage (national 
average)” as of May 2009 [15].
g
Time cost for collection of consent forms, and meeting with school staffs, and vendors. Evaluation research cost was excluded.
h
Composed of the vendor’s material and labor costs.













Yoo et al. Page 17
i
52% of the administered doses that were provided by Vaccine-for-children (VFC) for free. From a societal perspective, we assigned $10.40 per 
dose as the vaccine purchase cost, which is the weighted average prices of TIV (80% of doses administered in this demonstration) and LAIV (20%) 
as of May 2009 listed in the CDC website [16].
j
The values in the rows for subtotal costs and total costs indicate the mean and 95% confidence interval of Monte Carlo Simulation results (10,000 
iterations) using the distributions defined in the rows for component costs.
*
Falls between the 25th percentile ($13.42) and the median/mean ($21.44/$38.23) cost [per dose] for providing influenza vaccination in private 
pediatric practices estimated by Yoo et al. [10].
**
Below the lower limit of the cost range ($11.21, $16.81) [per child vaccinated] in the reminder program (using letters and/or automated 
telephone message) estimated by Lieu et al. [28].
***
Falls within the cost range ($11.21, $16.81) [per child vaccinated] in the reminder program (using letters and/or automated telephone message) 
estimated by Lieu et al. [28].
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Table 3
Cost analysis and cost-effectiveness analysis of the “first clinics” in school-located seasonal influenza 
vaccination (SLV-I) during the 2009–2010 season (2009 dollar value)
Cost analysis a Cost-effectiveness analysis b
Vaccinated at school Vaccinated anywhere c
Cost ($ per dose) ICER d ($-per-incremental-student- vaccinated)
COMPONENT COSTS e
(A) School Cost f $6.58 ($4.25, $9.77) $8.22 ($5.31, $12.22) $9.55 ($6.39, $12.10)
(B) Project Cost g $16.52 ($10.67, $24.54) $20.64 ($13.33, $30.66) $23.97 ($16.05, $30.38)
(C) Vendor Cost (= C1+ C2 ) $27.08 ($22.02, $34.02) $33.81 ($27.49, $42.48) $39.27 ($32.43, $58.69)
 (C1) vaccine administration h $14.29 ($9.23, $21.23) $17.84 ($11.52, $26.51) $20.72 ($13.88, $26.26)
 (C2) vaccine purchase (VFC dose =$10.40)i $12.79 $15.97 $18.55
 (C3) vaccine purchase (VFC dose = $0)i $7.31 $9.13 $10.61
(D) Averted parents’ costs (i.e., to visit medical 
practices for a child’s influenza vaccination)
$35.08 $35.08 $35.08
SUBTOTAL COSTS j
Subtotal Net Cost 1: (A + B) - (D) −$10.99 (−$16.67, −$4.80) −$4.94** (−$12.02, $2.65) −$2.28*** (−$8.52, $3.55)
Subtotal Direct Cost 2: (A + B + C1) $39.06 ($31.57, $46.93) $48.76 ($39.42, $58.69) $53.10 ($44.99, $60.90)
Subtotal Direct Cost 3: (A + B + C1 + C3) $46.38 ($39.07, 54.24) $57.86 ($48.57, $67.62) $63.74 ($55.89, $71.44)
TOTAL COSTS j
Total Direct Cost 1: (A + B + C) $51.79 ($44.37, $59.63) $64.67 ($55.46, $74.34) $76.27 ($65.12, $89.26)
Total Net Cost 2: (A + B + C1) - (D) $3.90* (−$3.52, $11.74) $13.67 ($4.45, $23.35) $18.05 ($9.85, $25.86)
Total Net Cost 3: (A + B + C) - (D) $16.69 ($9.44, $24.50) $29.63 ($20.34, $39.34) $41.12 ($30.05, $54.27)
a
Based on 1724 doses.
b
Based on 1381 students, identified as receiving at least the 1st dose at the SLV-I schools in the vendor’s data.
c
Broader perspective accounting for the fact that among children attending SLV-I schools a smaller proportion of children vaccinated elsewhere 
(i.e., their primary care doctor’s office) than control schools. Namely, Incremental effectiveness declined from 15.3% to 13.2% ICER for 
components (A/B/C1) inflated by (15.3%/13.2%).
d
ICER = incremental cost-effectiveness ratio [$-per-incremental-student-vaccinated at least 1st dose in the school-located seasonal influenza 
vaccination (SLV-I), compared to control schools]
e
The values in the rows for component costs indicate the triangular distributions defined by the likeliest value, (minimum value and maximum 
value). The likeliest value is the overall mean of the SLV-I schools. The minimum and the maximum values were selected among the four 
subgroups of the SLV-I schools, based on geographic area (urban or suburban) and the intervention intensity (high or low).
f
Composed of material cost and labor cost. Material cost includes information distribution (to parents) costs such as paper, mailing, and phone. 
Labor cost was calculated through “the time spent for the project by school staffs” multiplied by “category-specific hourly wage (national 
average)” as of May 2009 [15].
g
Time cost for collection of consent forms, and meeting with school staffs, and vendors. Evaluation research cost was excluded.
h
Composed of the vendor’s material and labor costs.
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i
52% of the administered doses that were provided by Vaccine-for-children (VFC) for free. From a societal perspective, we assigned $10.40 per 
dose as the vaccine purchase cost, which is the weighted average prices of TIV (80% of doses administered in this demonstration) and LAIV (20%) 
as of May 2009 listed in the CDC website [16].
j
The values in the rows for subtotal costs and total costs indicate the mean and 95% confidence interval of Monte Carlo Simulation results (10,000 
iterations) using the distributions defined in the rows for component costs.
*
Below the 25th percentile ($13.42) cost [per dose] and the median/mean ($21.44/$38.23) cost [per dose] for providing influenza vaccination in 
private pediatric practices estimated by Yoo et al. [10].
**
Below the lower limit of the cost range ($11.21, $16.81) [per child vaccinated] in the reminder program (using letters and/or automated 
telephone message) estimated by Lieu et al. [28].
***
Below the lower limit of the cost range ($11.21, $16.81) [per child vaccinated] in the reminder program (using letters and/or automated 
telephone message) estimated by Lieu et al. [28].
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Table 4
Cost analysis and Cost-effectiveness analysis of the “second clinics” in school-located seasonal influenza 
vaccination (SLV-I) during the 2009–2010 season [2009 dollar value]
Cost analysis a Cost-effectiveness analysis b
Vaccinated at school Vaccinated anywhere c
Cost ($ per dose) ICER d ($-per-incremental-student-vaccinated)
COMPONENT COSTS e
(A) School Cost f $15.07 ($9.73, $22.39) $18.84 ($12.16, $27.98) $21.86 ($14.64, $27.71)
(B) Project Cost g $37.84 ($24.43, $56.21) $47.26 ($30.52, $70.21) $54.89 ($36.76, $69.57)
(C) Vendor Cost (= C1+ C2 ) $45.51 ($33.92, $61.40) $56.83 ($42.36, $76.67) $66.01 ($50.33, $78.70)
(C1) vaccine administration h $32.72 ($21.13, $48.61) $40.86 ($26.39, $60.70) $47.46 ($31.78, $60.15)
(C2) vaccine purchase (VFC dose =$10.40)i $12.79 $15.97 $18.55
(C3) vaccine purchase (VFC dose = $0) i $7.31 $9.13 $10.61
(D) Averted parents’ costs (i.e., to visit medical 
practices for a child’s influenza vaccination)
$35.08 $35.08 $35.08
SUBTOTAL COSTS j
Subtotal Net Cost 1: (A + B) - (D) $20.12 ($7.42, $33.72) $33.86** ($17.53, $50.88) $40.08*** ($25.97, $53.56)
Subtotal Direct Cost 2: (A + B + C1) $89.36 ($72.63, $106.89) $111.76 ($90.71, $133.63) $121.68 ($103.02, $139.11)
Subtotal Direct Cost 3: (A + B + C1 + C3) $96.74 ($79.78, $114.56) $120.97 ($99.65, $143.78) $132.33 ($113.90, $149.74)
TOTAL COSTS j
Total Direct Cost 1: (A + B + C) $102.22 ($84.99, $119.94) $127.69 ($106.54, $150.24) $140.15 ($121.80, $158.10)
Total Net Cost 2: (A + B + C1) - (D) $54.48* ($37.64, $72.41) $76.39 ($55.11, $98.95) $86.41 ($68.49, $103.60)
Total Net Cost 3: (A + B + C) - (D) $67.20 ($50.61, $85.42) $92.69 ($71.49, $114.90) $105.00 ($86.49, $122.90)
a
Based on 1724 doses.
b
Based on 1381 students, identified as receiving at least the 1st dose at the SLV-I schools in the vendor’s data.
c
Broader perspective accounting for the fact that among children attending SLV-I schools a smaller proportion of children vaccinated elsewhere 
(i.e., their primary care doctor’s office) than control schools. Namely, Incremental effectiveness declined from 15.3% to 13.2% ICER for 
components (A/B/C1) inflated by (15.3%/13.2%).
d
ICER = incremental cost-effectiveness ratio [$-per-incremental-student-vaccinated at least 1st dose in the school-located seasonal influenza 
vaccination (SLV-I), compared to control schools]
e
The values in the rows for component costs indicate the triangular distributions defined by the likeliest value, (minimum value and maximum 
value). The likeliest value is the overall mean of the SLV-I schools. The minimum and the maximum values were selected among the four 
subgroups of the SLV-I schools, based on geographic area (urban or suburban) and the intervention intensity (high or low).
f
Composed of material cost and labor cost. Material cost includes information distribution (to parents) costs such as paper, mailing, and phone. 
Labor cost was calculated through “the time spent for the project by school staffs” multiplied by “category-specific hourly wage (national 
average)” as of May 2009 [15].
g
Time cost for collection of consent forms, and meeting with school staffs, and vendors. Evaluation research cost was excluded.
h
Composed of the vendor’s material and labor costs.
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i
52% of the administered doses that were provided by Vaccine-for-children (VFC) for free. From a societal perspective, we assigned $10.40 per 
dose as the vaccine purchase cost, which is the weighted average prices of TIV (80% of doses administered in this demonstration) and LAIV (20%) 
as of May 2009 listed in the CDC website [16].
j
The values in the rows for subtotal costs and total costs indicate the mean and 95% confidence interval of Monte Carlo Simulation results (10,000 
iterations) using the distributions defined in the rows for component costs.
*
Above the median/mean ($21.44/$38.23) and the 75th percentile ($38.84) cost [per dose] for providing influenza vaccination in private pediatric 
practices estimated by Yoo et al. [10].
**
Above the upper limit of the cost range ($11.21, $16.81) [per child vaccinated] in the reminder program (using letters and/or automated 
telephone message) estimated by Lieu et al. [28].
Above the upper limit of the cost range ($11.21, $16.81) [per child vaccinated] in the reminder program (using letters and/or automated telephone 
message) estimated by Lieu et al. [28].
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